MOBİL HİDROLİK TELESKOBİK VİNÇLERDE YÜK SALINIM KONTROLÜ

Bu çalışmada, mobil hidrolik teleskobik bir vincin öncelikle tasarımı yapılmış ve burada bir yük ile vinç tanımlanmıştır. Tasarlanan teleskopik vinç gerçek sistemdeki veriler dahil edilerek Matlab/Simulink programında modellenmiştir. Giriş sinyalleri etkisiyle oluşan salınım ölçülüp bu salınımı kabul edilebilir toleranslar dahiline düşürebilecek kontrolcü tasarlanmıştır. Çalışmanın ana hedefi, mobil teleskobik vinçlerin kaldırma silindirleri ve dönme merkezindeki tork tahriki ile hareket etmesi sonucu teleskobik vince bir halat vasıtasıyla bağlı olan yükün x, y, z referans eksenlerine göre açılı bir şekilde oluşan salınımını kontrolcü kullanarak minimize etmektir. Sistemin başarı kriteri, uygulamada ergonomik bir çalışma zemini hazırlayacak şekilde salınımı azaltmak olacaktır. Göz önüne alınması gereken bir diğer nokta ise vinci kullanacak operatörden bağımsız bir şekilde bu kontrolü sağlamak olacaktır.

MOBİL HİDROLİK TELESKOBİK VİNÇLERDE YÜK SALINIM KONTROLÜ

Bu çalışmada, mobil hidrolik teleskobik bir vincin öncelikle tasarımı yapılmış ve burada bir yük ile vinç tanımlanmıştır. Tasarlanan teleskopik vinç gerçek sistemdeki veriler dahil edilerek Matlab/Simulink programında modellenmiştir. Giriş sinyalleri etkisiyle oluşan salınım ölçülüp bu salınımı kabul edilebilir toleranslar dahiline düşürebilecek kontrolcü tasarlanmıştır. Çalışmanın ana hedefi, mobil teleskobik vinçlerin kaldırma silindirleri ve dönme merkezindeki tork tahriki ile hareket etmesi sonucu teleskobik vince bir halat vasıtasıyla bağlı olan yükün x, y, z referans eksenlerine göre açılı bir şekilde oluşan salınımını kontrolcü kullanarak minimize etmektir. Sistemin başarı kriteri, uygulamada ergonomik bir çalışma zemini hazırlayacak şekilde salınımı azaltmak olacaktır. Göz önüne alınması gereken bir diğer nokta ise vinci kullanacak operatörden bağımsız bir şekilde bu kontrolü sağlamak olacaktır

UVEITIS RELATED FACTORS IN PATIENTS WITH SPONDYLOARTHRITIS

Annual European Congress of Rheumatology (EULAR) -- JUN 12-15, 2019 -- Madrid, SPAIN[No Abstract Available]European League Against Rheumatis

Smoking May Be Related to Sacroiliitis in Enteropathic Arthritis Patients: Treasure Real-Life Preliminary Data

Annual European Congress of Rheumatology (EULAR) -- JUN 12-15, 2019 -- Madrid, SPAIN[No Abstract Available]European League Against Rheumatis

Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry

Objective: Our aim is to test the validity of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome, to assess the psoriasis severity within the scope of rheumatology. Methods: Within the PsA international database (PSART-ID), 571 patients had PSI, while 322 of these also showed body surface area (BSA). Correlations between PSI, BSA, and other patient- and physician-reported outcomes were investigated. Results: There was a good correlation between PSI and BSA (r=0.546, p<0.001), which was even higher for mild psoriasis (BSA<3 (n=164): T-0.608, p<0.001). PSI significantly correlated with fatigue, pain, and patient and physician global parameters (p<0.001). Conclusion: PSI has a good correlation with other patient- and physician-reported outcomes, and our findings support its use in rheumatology practice

Adaptation and psychometric testing of the Turkish evaluation of daily activity questionnaire in people with rheumatoid arthritis

Purpose: The aims were to translate the Evaluation of Daily Activity Questionnaire (EDAQ) into Turkish, then test validity and reliability in people with rheumatoid arthritis (RA) in Turkey. Material and Methods: Phase 1: The EDAQ was forward and backward translated, culturally adapted following cognitive debriefing interviews with participants with RA (n=10) and finalised by an expert committee. Phase 2: Participants (n=215) completed a questionnaire including the EDAQ, Health Assessment Questionnaire (HAQ), and Short-Form 36 v1 (SF-36v1). Two weeks later, the EDAQ was again completed for test-retest reliability (n=82:38%). Internal construct validity was assessed using Rasch analysis. Internal consistency, concurrent validity, and test-retest reliability were assessed. Results: Following cultural adaptation, one item was removed, and examples increased or changed. Cronbach’s α values were 0.71 – 0.93 for all EDAQ domains, i.e., acceptable to good. The EDAQ met Rasch model requirements for fit (excellent construct validity: p>0.05). Concurrent validity was moderate to strong for most EDAQ domains with HAQ (rs 0.49-0.81) and SF-36-v1 Physical Function (rs 0.42-0.70). There was excellent test-retest reliability for all domains (ICC (2,1): 0.95-1.00).Conclusion: The Turkish EDAQ is a valid, reliable measure of daily activity ability for use in practice and research with Turkish speakers with RA

Updating the Psoriatic Arthritis (PsA) core domain set:A report from the PsA workshop at OMERACT 2016

OBJECTIVE: To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS).METHODS: At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants.RESULTS: We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient's global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda.CONCLUSION: The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.</p

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials

© 2017 Published by the BMJ Publishing Group Limited. Objective To identify a core set of domains (outcomes) to be measured in psoriatic arthritis (PsA) clinical trials that represent both patients' and physicians' priorities. Methods We conducted (1) a systematic literature review (SLR) of domains assessed in PsA; (2) international focus groups to identify domains important to people with PsA; (3) two international surveys with patients and physicians to prioritise domains; (4) an international face-To-face meeting with patients and physicians using the nominal group technique method to agree on the most important domains; and (5) presentation and votes at the Outcome Measures in Rheumatology (OMERACT) conference in May 2016. All phases were performed in collaboration with patient research partners. Results We identified 39 unique domains through the SLR (24 domains) and international focus groups (34 domains). 50 patients and 75 physicians rated domain importance. During the March 2016 consensus meeting, 12 patients and 12 physicians agreed on 10 candidate domains. Then, 49 patients and 71 physicians rated these domains' importance. Five were important to >70% of both groups: musculoskeletal disease activity, skin disease activity, structural damage, pain and physical function. Fatigue and participation were important to >70% of patients. Patient global and systemic inflammation were important to >70% of physicians. The updated PsA core domain set endorsed by 90% of OMERACT 2016 participants includes musculoskeletal disease activity, skin disease activity, pain, patient global, physical function, health-related quality of life, fatigue and systemic inflammation. Conclusions The updated PsA core domain set incorporates patients' and physicians' priorities and evolving PsA research. Next steps include identifying outcome measures that adequately assess these domains

Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies

OBJECTIVES: To evaluate the systemic phenotype associated with the presence of isolated anti-La/SSB antibodies in a large international registry of patients with primary Sjögren's syndrome (pSS) fulfilling the 2002 classification criteria.METHODS: The Big Data Sjögren Project Consortium is an international, multicentre registry created in 2014. Baseline clinical information from leading centres on clinical research in SS of the 5 continents was collected. Combination patterns of anti-Ro/SSA-La/SSB antibodies at the time of diagnosis defined the following four immunological phenotypes: double positive (combined Ro/SSA and La/SSB,) isolated anti-Ro/SSA, isolated anti-La/SSB, and immunonegative.RESULTS: The cohort included 12,084 patients (11,293 females, mean 52.4 years) with recorded ESSDAI scores available. Among them, 279 (2.3%) had isolated anti-La/SSB antibodies. The mean total ESSDAI score at diagnosis of patients with pSS carrying isolated anti-La/SSB was 6.0, and 80.4% of patients had systemic activity (global ESSDAI score ≥1) at diagnosis. The domains with the highest frequency of active patients were the biological (42.8%), glandular (36.8%) and articular (31.2%) domains. Patients with isolated anti-La/SSB showed a higher frequency of active patients in all ESSDAI domains but two (articular and peripheral nerve) in comparison with immune-negative patients, and even a higher absolute frequency in six clinical ESSDAI domains in comparison with patients with isolated anti-Ro/SSA. In addition, patients with isolated anti-La/SSB showed a higher frequency of active patients in two ESSDAI domains (pulmonary and glandular) with respect to the most active immunological subset (double-positive antibodies). Meanwhile, systemic activity detected in patients with isolated anti-La/SSB was overwhelmingly low. Even in ESSDAI domains where patients with isolated anti-La/SSB had the highest frequencies of systemic activity (lymphadenopathy and muscular), the percentage of patients with moderate or high activity was lower in comparison with the combined Ro/SSA and La/SSB group.CONCLUSIONS: Patients carrying isolated La/SSB antibodies represent a very small subset of patients with a systemic SS phenotype characterised by a significant frequency of active patients in most clinical ESSDAI domains but with a relative low frequency of the highest severe organ-specific involvements. Primary SS still remains the best clinical diagnosis for this subset of patients